Immune cell profiles of metastatic HER2-positive breast cancer patients according to the sites of metastasis
Open Access
- 24 November 2021
- journal article
- research article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 191 (2) , 443-450
Abstract
Purpose: Recent works have characterized that metastatic site can affect the tumour immune profiles and efficiency of cancer immunotherapies. The prognosis of HER2-positive breast cancer is associated with the characteristics of the tumour immune microenvironment, with immunological cells playing a central role in efficiency of HER2-targeted antibodies. Here we investigated the prognostic significance of different metastatic sites and their correlation to tumour immune profiles in HER2-positive breast cancer treated with trastuzumab. Methods: We collected all (n = 54) HER2-positive metastatic breast cancer patients treated with trastuzumab containing regimens at Oulu University Hospital 2009–2014. Pathological and clinical data were collected from electronic patient records. The tumour immune profiles were analysed from pre-treatment primary tumours using well-characterized immunological markers with computer-assisted immune cell counting. Results: Of the metastatic sites, only liver metastases were associated with poor prognosis (hazard ratio 1.809, 95% confidence interval 1.004–3.262), especially when presented as the primary site of metastases. Of the other sites, pulmonary metastases characterized a patient profile with trend to improved survival. Of the studied tumour immunological markers, patients with liver metastases had low densities of CD3+ T cells (p = 0.030) and M1-like macrophages in their primary tumours (p = 0.025). Of the other studied markers and sites, patients with pulmonary metastases had low STAB1+-immunosuppressive macrophage density in their primary tumours. Conclusion: Our results suggest that the site of metastasis is associated with prognosis in HER2-positive breast cancer, highlighted by the poor prognosis of liver metastases. Furthermore, liver metastases were associated with adverse tumour immune cell profiles.Keywords
All Related Versions
Funding Information
- Syöpäsäätiö
- Oulun Yliopisto
- University of Oulu including Oulu University Hospital
This publication has 28 references indexed in Scilit:
- An improved image analysis method for cell counting lends credibility to the prognostic significance of T cells in colorectal cancerVirchows Archiv, 2012
- Tumor-Infiltrating CD8+Lymphocytes Predict Clinical Outcome in Breast CancerJournal of Clinical Oncology, 2011
- Metastatic Behavior of Breast Cancer SubtypesJournal of Clinical Oncology, 2010
- High Risk of Recurrence for Patients With Breast Cancer Who Have Human Epidermal Growth Factor Receptor 2–Positive, Node-Negative Tumors 1 cm or SmallerJournal of Clinical Oncology, 2009
- Trastuzumab — Mechanism of Action and Use in Clinical PracticeNew England Journal of Medicine, 2007
- Randomized Phase II Trial of the Efficacy and Safety of Trastuzumab Combined With Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Administered As First-Line Treatment: The M77001 Study GroupJournal of Clinical Oncology, 2005
- Pilot Study of the Mechanism of Action of Preoperative Trastuzumab in Patients with Primary Operable Breast Tumors Overexpressing HER2Clinical Cancer Research, 2004
- Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian CancerScience, 1989
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neuOncogeneScience, 1987
- The Atomic Structure of Mengo Virus at 3.0 Å ResolutionScience, 1987